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Although multiple myeloma remains incurable outside of allogeneic hematopoietic stem cell transplantation, novel agents made
availableonlyinthelastfewdecadeshavenonethelesstremendouslyimprovedthelandscapeofmyelomatreatment.Lenalidomide,
of the immunomodulatory class of drugs, is one of those novel agents. In the non-transplant and relapsed/refractory settings,
lenalidomide clearly beneﬁts patients in terms of virtually all meaningful outcomes including overall survival. Data supporting the
usage of lenalidomide as part of treatment approaches incorporating high-dose chemotherapy with autologous stem cell support
(ASCT) are less mature as pertains to such long-term outcomes and toxicity, and lenalidomide is not currently approved by regu-
latory agencies for use in the context of ASCT in either the United States or Europe. That said, relatively preliminary eﬃcacy data
describing lenalidomide as a component of ASCT-based treatment approaches to MM are indeed promising, and consequently
lenalidomide’s role in ASCT-based treatment strategies is growing. In this review we summarize existing data that pertains to
lenalidomide in the speciﬁc context of ASCT, and we share our thoughts on how our own group applies these data to approach
this complex issue clinically.
1.Introduction
Multiple myeloma (MM) is a malignancy of plasma cells that
strikes roughly 20,000 and kills 10,000 US Americans yearly
[1]. Outside of allogeneic stem cell transplantation, MM
remains incurable, albeit increasingly treatable, thanks to the
advent of novel agents including those that are currently
approved by the United States Food and Drug Administra-
tion (FDA) and European Medicines Agency (EMA)—bor-
tezomib, thalidomide, and lenalidomide.
Regarding the latter, the initial phase one study of
lenalidomide (Revlimid), then known as CC-5013, ﬁrst
appeared in the scientiﬁc literature in 2002 and attention
rapidly focused on CC-5013’s activity even in multiply
relapsed and refractory MM (RRMM) [2]. That study and
others led to the later deﬁnitive phase three MM-009 and
010 trials, which showed overall survival beneﬁts for RRMM
patients on lenalidomide and dexamethasone in contrast
to those on dexamethasone alone [3, 4]. FDA and EMA
approval for lenalidomide followed, and lenalidomide and
dexamethasone became established as a standard of care
for RRMM. Subsequent clinical trials have further explored
the role of lenalidomide as a part of treatment strategies
for newly diagnosed MM (NDMM) that both include or
exclude high-dose therapy with autologous hematopoietic
stem cell transplantation (ASCT), although lenalidomide
remains without approval for usage in the setting of ASCT
by either FDA or EMA. In the current discussion, we focus
on lenalidomide speciﬁcally as part of ASCT-based therapy
approaches for MM.
2. Lenalidomide Induction prior to ASCT
The combination of dexamethasone and thalidomide com-
pared favorably, in a retrospective study, with the ear-
lier induction standard of vincristine, doxorubicin (Adri-
amycin), and dexamethasone (VAD), and thalidomide plus
dexamethasone became an attractive therapeutic option
for NDMM. However, signiﬁcant nonhematological toxicity2 Advances in Hematology
Table 1: Select lenalidomide-based, pre-ASCT induction regimens for NDMM.
RD Lenalidomide 25mg orally days 1–21 and dexamethasone 40mg orally days 1–4, 9–12, 17–20. 28 day cycles [9]
Rd Lenalidomide 25mg orally days 1–21 and dexamethasone 40mg orally weekly. 28 day cycles [9]
BiRD
Clarithromycin 500mg orally twice daily continuously, starting on day 2 of cycle 1; lenalidomide 25mg orally days 3–21 of
cycle 1, then days 1–21 of later cycles; dexamethasone 40mg orally days 1, 2, 3, 8, 15, and 22 of cycle 1, then days 1, 8, 15, and
22 of later cycles. 28 day cycles [10]
RVD Lenalidomide 25mg orally days 1–14; bortezomib 1.3mg/m2 IV days 1, 4, 8, 11; dexamethasone 20mg orally days 1, 2, 4, 5, 8,
9, 11, 12. 21 day cycles [11]
CRD Cyclophosphamide 300mg (ﬁxed dose) orally days 1, 8, and 15; lenalidomide 25mg orally days 1–21; dexamethasone 40mg
orally days 1, 8, 15, 22. 28 day cycles [12]
RVCD Lenalidomide 25mg orally days 1–14; bortezomib 1.3mg/m2 IV days 1, 4, 8, 11; cyclophosphamide 500mg/m2 orally days 1
and 8; dexamethasone 40mg orally days 1, 8, 15. 21 day cycles [13]
RVDDoxil
Lenalidomide 25mg orally days 1–14; bortezomib 1.3mg/m2 IV days 1, 4, 8, and 11; dexamethasone 20mg orally days 1, 2, 4,
8, 11, and 12 for cycles 1–4 and 10mg on the same schedule for later cycles; liposomal doxorubicin 30mg/m2 IV on day 4. 21
day cycles [14]
CarRD Carﬁlzomib 20–36mg/m2 days 1, 2, 8, 9, 15, 16; lenalidomide 25mg orally days 1–21; dexamethasone 20–40mg days 1, 8, 15,
and 22. 28 day cycles (dose of carﬁlzomib and dexamethasone was variable in this phase 1/2 study) [15]
aﬀectedalargeproportionofpatients[5].Thalidomide’seﬃ-
cacyandtoxicity both engenderedinterest inlenalidomide as
a possibly more potent and less toxic analog of thalidomide
that could replace thalidomide in both the ASCT and non-
ASCT settings.
Lenalidomide’sactivityinNDMMpre-ASCTwasunmis-
takable from the outset. In its ﬁrst major, phase 2 study,
namely, that of the RDregimen (lenalidomide and high-dose
dexamethasone; see Table 1 for details regarding regimens),
91%ofpatientsrespondedand44%proceededtoASCTafter
four cycles. Toxicity was excessive, and the toxicity proﬁle
in general resembled that seen in prior trials of high-dose
dexamethasone alone. The follow-up randomized trial by
the Southwest Oncology Group (SWOG) of three cycles of
dexamethasone alone versus RD induction, followed in each
arm by the same drugs given at lower doses as maintenance,
conﬁrmed lenalidomide’s activity in NDMM, manifesting
as signiﬁcantly increased response rates. However, that trial
also provided clear evidence of lenalidomide’s toxicity when
used with high-dose dexamethasone, for example, a 23.5%
rateofvenousthromboemboliceventsforRDdespiteaspirin
prophylaxis versus 5% for dexamethasone alone (P<0.001)
[6]. These observations of high activity and toxicity early on
in the SWOG study gave rise to subsequent study of lenalido-
mide with lower dose, that is, weekly, dexamethasone, largely
as a result of requests by patient advocacy groups [7, 8].
TheECOG’sE4A03study(n = 445)includedbothASCT
candidates and noncandidates and was designed with the
primary endpoint of testing noninferiority of lenalidomide
given with low-dose (weekly) dexamethasone (i.e., the Rd
regimen; Table 1) to RD. Patients on RD demonstrated more
objective responses than patients taking Rd (overall response
rate ORR 81% versus 70%, P = 0.008; Figure 1), but at
the price of inferior one-year overall survival (87% one-year
o v e r a l ls u r v i v a lO Sf o rR Dv e r s u s9 6 %f o rR d ,P = 0.0002).
Closer inspection reveals that the increased mortality with
RD was likely associated with the higher rate of grade 3 or
greater venous thromboembolic events, infection, or cardiac
complications than Rd and that toxicity occurred primarily
in the ﬁrst four months of therapy. In terms of ASCT, 39.5%
of patients in this study attempted ASCT after four cycles
of induction, 98% of whom did so successfully. Among
ASCT patients, median three-year OS was 92% and similar
between the RD and Rd groups. RD and Rd both emerged as
clearly eﬀective regimens for pre-ASCT induction. Although
the OS one-year beneﬁt to Rd has resulted in the more
widespread usage of low-dose dexamethasone than high-
dose, for patients going to ASCT, one should recall that the
survival beneﬁt with Rd was speciﬁcally in patients not going
for ASCT [9].
Since initial reports on E4A03, investigators have sought
to build on the lenalidomide/dexamethasone backbone to
create even more eﬃcacious pre-ASCT regimens. Several
have been described, and the result comprises a signiﬁcant
contribution to the increasingly complex combinations that
constitute modern oncology; BiRD, RVD, CRD, RVCD, and
RVDDoxil are perhaps the most robustly described exam-
ples. An overview discussion of each of these regimens
follows. The reader will note the paucity of head-to-head
studies of most of these regimens, and this discussion hence
largely limits itself to comparisons of single-arm trials. The
important caveatsofcross-trialcomparisons thereforeapply:
selection bias (i.e., diﬀerences in patient selection both for
trial participation and for later ASCT), variable durations
of planned duration of protocol therapy and followup, and
reporting of diﬀerent, often surrogate endpoints, among
other limitations. We oﬀer Figure 1 partially to visually sum-
marize available data, but also to underscore the diﬃculty,
if not impossibility, of selecting the “correct” induction
regimen based on what we know about these combinations.
Starting with BiRD, Niesvizky et al. sought to improve
upon their earlier experience with the combination of
thalidomide, dexamethasone, and the macrolide antibiotic
clarithromycin (Biaxin), the latter of which had preclinical
data supporting both independent cytotoxicity and poten-
tiation of dexamethasone’s cytotoxic eﬀect in MM [16].
Building on Rd, this group devised BiRD—Rd plus twice
daily clarithromycin (Table 1). In a single-arm trial (n = 72),Advances in Hematology 3
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Figure 1: Reported response rates for lenalidomide-based induction regimens for MM. Rates depicted are those that could be ascertained
either directly using reported data or as calculated using reported data. (a) Response rates after four cycles of therapy. Deeper response rates
are not displayed due to inconsistent reporting in referenced sources. (b) Best response reached on study. Rates after four cycles could be
envisioned as a measure of expected response pre-ASCT, whereas best response rate may represent a regimen’s maximum potential, but only
after more cycles than a patient would usually be administered as pre-ASCT induction. Data was gleaned from the following sources: RD
a n dR d[ 9]; RVD [11]; CRD [12]; BiRD [10]; and RVDDoxil [14].
90.3% of patients had an objective response with 73.6% of
patients achieving a very good partial response (VGPR) or
better(Figure 1).25%ofpatientsunderwentASCTafterfour
or more cycles with a 5.5% (one patient) mortality rate.
Two-year event-free survival for the ASCT group was 85.2%
[10]. A separate case-control study comparing this cohort to
matched patients who received Rd showed that BiRD was
associated with notably deeper responses with induction
(e.g., 73.6% versus 33.3% VGPR or better, P<0.001) and
a statistically insigniﬁcant trend toward improved OS. Grade
3 or greater toxicity was also increased with BiRD and was
largely hematological. Important diﬀerences in these trials
are worth noting, including that the median duration of
therapy for BiRD was longer than Rd (11.8 versus 6 months)
and BiRD patients undergoing ASCT did so much later (13.5
versus 5.9 months). The authors state that it was unclear
to them why BiRD patients remained on therapy so much
longer than Rd patients, but it stands to reason that the
longer duration of therapy augmented both toxicity and
ORR [17].
RVD (lenalidomide, bortezomib, and dexamethasone;
Table 1)—a logical extrapolation of Rd to incorporate the
proteasome inhibitor bortezomib—has perhaps gained the
widest implementation by community oncologists after the
initial phase 1/2 study demonstrated a 100% ORR and 74%
VGPR or better rate in 35 phase 2 patients receiving a
median of 10 cycles at the maximum tolerated dose (MTD)
established in the earlier, phase 1 component of the study
(Figure 1). 28 (42%) of all patients on protocol underwent
ASCT at some point after cycle four with no signiﬁcant
diﬃculties reported. Among ASCT patients, the authors
observed a 100% ORR with 57% of patients attaining VGPR
or better. The median PFS for all patients at 18 months was
75%, and median OS had not been reached at the time of
publication [11].
With CRD (cyclophosphamide, lenalidomide, dexam-
ethasone; Table 1), investigators again sought to improve
lenalidomide/dexamethasone, this time by adding weekly
oral cyclophosphamide in three weeks of a four week cycle.
In this single arm trial (n = 53), the ORR was 85% with
47% of patients achieving VGPR or better (Figure 1). 58% of
patients at some point went on to attempt ASCT, but, in 25%
of cases, hematopoietic stem cell mobilization with G-CSF
wasunsuccessful.Themajorityofthosepatientscouldbesal-
vaged using either cyclophosphamide or plerixafor. In those
patients that actually underwent ASCT, no unexpected com-
plications were noted, and, in all patients, the median dura-
tion of response was 30.9 months. In general, the regimen
was well tolerated, with the main toxicity being neutropenia;
almost 60% of patients experienced grade 3 or 4 neutropenia
[12].
RVCD has also been tested, with the idea of com-
bining lenalidomide, bortezomib, cyclophosphamide, and
dexamethasone into a single pre-ASCT induction regimen.
In the initial phase 1 EVOLUTION study—the single
randomized study available for all the induction regimens
under discussion—patients received RVD (n = 42), RVCD
(n = 41), or VCD (bortezomib, cyclophosphamide, and
dexamethasone; n = 32) (Table 1). An update for the sub-
sequent phase 2 component of this trial was presented at the
American Society of Hematology meeting in 2010, in which
additional 17 patients were given modiﬁed VCD (mVCD), in
which the week three treatment break for cyclophosphamide
was eliminated. Ultimately all regimens proved to have
signiﬁcant activity as measured by ORR, ranging from 78%
(VCD) to 100% (mVCD) and ≥VGPR rates ranging from4 Advances in Hematology
41% (VCD) to 90% (RVCD and mVCD; Figure 1). Toxicity
was similar and manageable across all groups. At the time
of the ﬁrst paper’s publication, 13 of the original 25 patients
had undergone ASCT with only one patient requiring a
secondattemptatstemcellcollection.Speciﬁcdetailsregard-
ing mobilization are not yet reported, nor is longer-term
followup available for this trial [13, 18].
Lastly, RVDDoxil—that is, RVD with liposomal dox-
orubicin (Doxil; Table 1)—has also been examined in the
context of pre-ASCT induction for NDMM. In the published
phase 1/2 study (n = 72 evaluable patients), 39 patients
were treated at what was found to be the MTD. 58 patients
(81%) underwent stem cell collection after a median of 3
to 8 cycles, 40 of whom (69%) received cyclophosphamide,
plerixafor, or both in addition to standard G-CSF for stem
cellmobilization. 49 patients (68%) proceeded to ASCTafter
four to eight cycles of RVDDoxil. ORR in all patients (ASCT
and non-ASCT) receiving the MTD was 95% with 64%
achieving VGPR or better at any point (Figure 1). ASCT
proceeded without unexpected complications in all patients.
Long-term followup is unavailable, but 18-month PFS for
all patients was 81.6%; 93.5% for patients who underwent
ASCT and 64.3% for patients who did not. Similar to the
other studies discussed, hematological toxicity, neuropathy,
fatigue were the primary manifestations of toxicity, although
they were generally manageable with appropriate dose-
reductions [14].
With the exception of perhaps EVOLUTION, these clini-
caltrialswilllikelynotgreatlyaidcliniciansinsortingoutthe
obvious question of which induction regimen is best for the
patient moving toward ASCT. Future comparative studies
with long-term followup of meaningful endpoints are criti-
cal, particularly as the picture becomes even more complex
with upcoming trials looking at combinations of the lat-
est generation of novel agents, such as carﬁlzomib and
pomalidomide. Only the earliest data exist as of yet for
those agents in the pre-ASCT setting, but those data suggest
that these agents too can induce very deep responses pre-
ASCT. Jakubowiak et al., for example, reported their pilot
study in an oral abstract detailing carﬁlzomib, lenalidomide,
and dexamethasone (CarRD—our abbreviation; Table 1)a s
induction therapy for NDMM. CarRD preliminarily appears
to be at least as potent as the established regimens with
published data, with 65% of patients reaching VGPR or
better [15].
2.1. Stem Cell Mobilization and Collection after Lenalidomide-
Based Induction. Stem cell mobilization into the peripheral
blood and subsequent stem cell collection is the critical
prelude to ASCT, with the usual aim of collecting enough
cells to perform two ASCTs. Given that one of lenalido-
mide’s most common toxicities is myelosuppression, from
early on investigators have considered whether lenalidomide
could damage hematopoietic stem cells and hinder G-
CSF-induced mobilization. Further studies have examined
whether cyclophosphamide or plerixafor could be used to
overcome diﬃculties in mobilization that may be linked to
lenalidomide-based induction.
Kumaretal.retrospectivelyreviewed376eligiblepatients
who had undergone stem cell collection within 12 months
of starting MMf therapy. 12.8% of patients had received
lenalidomide and dexamethasone-based induction, whereas
the others received VAD, thalidomide + dexamethasone, or
dexamethasonealone.Formobilization,64.3%ofallpatients
received G-CSF alone and 33.6% received G-CSF with
cyclophosphamide. The decision to employ the latter was
made based on whether patients appeared to have “active
disease,” deﬁned as the presence of circulating plasma cells
at the time of mobilization. Of patients receiving G-CSF
alone, three completely failed to mobilize—all had received
lenalidomide for greater than six months. Furthermore, day
one collection yield and total daily collection of stem cells
correlated inversely with duration of lenalidomide therapy.
Among patients who received cyclophosphamide-based
mobilization, only ﬁve previously took lenalidomide as part
of their induction. Despite impaired mobilization, however,
no diﬀerence in engraftment kinetics was evident (denoting
lengthoftimeuntilperipheralbloodcellcountrecoveryafter
reinfusion of stem cells) [19]. Other retrospective studies
have since conﬁrmed the link between lenalidomide and
impaired mobilization. That said, the duration dependency
has not been evident in all studies, meaning that a longer
duration of lenalidomide therapy in some studies has
not predicted greater diﬃculty with mobilization [20, 21].
Given the episodic diﬃculty of G-CSF mobilization after
lenalidomide induction, subsequent studies have looked
at cyclophosphamide and plerixafor as potential tools for
overcoming diﬃculties with mobilization.
Cavallo et al. prospectively studied 346 patients who
had received four cycles of Rd followed by G-CSF and
cyclophosphamide for mobilization. In 21% of patients,
adequate stem cells for two ASCTs could not be collected
on the ﬁrst attempt; they therefore went on to a second
cyclophosphamide- and G-CSF-based mobilization. 8% of
patientsstillhadinadequatecellsforevenoneASCTafterthe
second attempt and hence could not undergo ASCT. An
additional 9% had enough cells for only one transplant,
that is, 17% of patients had what would be considered a
suboptimal collection using the gold standard mentioned.
Engraftmentkineticswereunimpaired.With91%ofpatients
achieving a successful mobilization at least for one ASCT,
however, four cycles of Rd followed by mobilization with G-
CSF and cyclophosphamide were felt by the authors to be a
reasonable strategy for patients going for ASCT.
The C-X-C chemokine receptor type 4 (CXCR4) antag-
onist plerixafor may also mitigate lenalidomide-related
impairment of stem cell mobilization. In one study, pler-
ixafor was given with G-CSF as an initial attempt at
mobilization (n = 20) or for remobilization in the case of an
initial failed stem cell mobilization (n = 40) and results were
retrospectively studied. Patients in both groups had received
a median of roughly four cycles of lenalidomide-containing
induction (range 1–20). 5% of patients receiving front-
line plerixafor versus 52.5% of patients receiving it as a
remobilizationstrategyfailedtoachievethegoalofcollection
for two ASCTs, although for most patients collection was
adequate for at least a single ASCT. It appeared that patientsAdvances in Hematology 5
undergoing remobilization who had received >3 cycles of
lenalidomide induction had a greater incidence of mobi-
lization failure despite plerixafor, although small sample
sizes precluded drawing deﬁnitive conclusions. Engraftment
kinetics were again acceptable. In summary, it appears
that plerixafor can to some degree overcome lenalidomide-
relatedimpairmentofstemcellmobilization,butnotentirely
[22].
2.2. Lenalidomide in the Pre-ASCT Setting: Our Approach.
Our approach to lenalidomide in the induction setting for
ASCT patients is as follows. Existing data support, albeit
not deﬁnitively, the concept that deep remissions going into
ASCT are a desirable aim—in many studies, they correlate
with long-term survival. Clearly, deep remissions in an
individual patient could reﬂect either disease biology OR
therapy selection, and so a causal link between induction
therapy selection and OS is currently lacking. We would refer
the reader to astute discussions on this controversial topic
that have been published already [23–25]. Caveats notwith-
standing, we believe that the extremely high response rates
seen with short-course, initial induction regimens such as
those discussed above, taken in combination with early hints
at unprecedented post-ASCT PFS durations and manageable
toxicity, will eventually translate into improvements in OS
as well. Furthermore, limiting the duration of therapy
limits toxicity in general, including perhaps lenalidomide-
mediatedimpairmentofstemcellcollection.Forthatreason,
we believe in “hard and fast” induction, in which we most
commonly oﬀer triple-drug regimens to ﬁt patients prior to
ASCT—either RVD as noted above, or cyclophosphamide,
bortezomib, and dexamethasone, depending on clinical
circumstances. We usually do not utilize four-drug regimens,
such as RVCD or RVDDoxil, because response rates do not
seem to be markedly improved as compared to three-drug
regimens (Figure 1), yet the potential for toxicity generally
rises.
Other groups have reported on other pre-ASCT triplet
regimens such as bortezomib, thalidomide, and dexametha-
sone [26]; bortezomib, doxorubicin, and dexamethasone
[27]. Those are also valid and well-tested options, but a com-
prehensive discussion of all described pre-ASCT induction
regimensgoesbeyondthescopeofthislenalidomide-focused
paper. Truly, with the plethora of currently available data
including unfortunately very few randomized trials, many of
these induction regimens could be argued for. Consequently
selection of a regimen presently depends heavily on provider
preference and patient comorbidities. Randomized clini-
cal trials are clearly needed to sort through the existing
equipoise, so the ﬁeld can move beyond personal and insti-
tutional preferences into an era of evidence-based selection
of induction regimens.
Whatever the speciﬁc regimen, we optimally limit dura-
tion of therapy to four but no more than six cycles of any
lenalidomide-containing induction prior to stem cell collec-
tion. For patients who do receive lenalidomide with their
induction, we generally mobilize stem cells with G-CSF and
cyclophosphamide 4g/m2,a n dw ea d dp l e r i x a f o ri nc a s e so f
poor mobilization with the ﬁrst two agents.
2.3. Lenalidomide Consolidation and Maintenance after
ASCT. Early studies investigating the long-term usage of
agents such as thalidomide and interferon-alpha were chal-
lenging, in the sense that interferon was overly toxic with
minimal beneﬁt [28] and thalidomide, although perhaps
more eﬃcacious, was also toxic and most patients could
not tolerate it on the long term [29–31]. With the idea
that lenalidomide may oﬀer a more potent, less toxic
maintenance therapy, several studies have examined the role
of lenalidomide after ASCT. Followup of the two major trials
driving the current discussion remains of relatively short
duration, and the most recent data are only available in
abstract form at the time at which we write this paper.
The CALGB 100104 trial has generated considerable
excitement for lenalidomide maintenance. 568 patients who
had received a variety of induction regimens usually includ-
ing at least one novel agent and who had stable disease or
better after single ASCT were randomized to either lenalido-
mide or placebo maintenance given at 5–15mg daily, based
on tolerance. An initial beneﬁt of almost doubling of time to
progressionledtounblindingandcross-overtolenalidomide
for 87% of placebo patients [32]. Data presented early in
2011 in an oral abstract supported an OS beneﬁt based on
an intention-to-treat analysis despite the crossover; 9% of
lenalidomide patients died versus 16.1% of placebo patients
with a median followup of 17.6 months (P<0.019).
Exploratory analyses suggest that the beneﬁt of lenalidomide
was present regardless of beta-2-microglobulin level but
statistical interactions between the eﬀect of lenalidomide
and other risk factors, such as cytogenetic or ﬂuorescent in
situ hybridization (FISH) abnormalities, have not yet been
reported [33].
Conversely, the Intergroupe Francophone du Myelome
(IFM) 2005-02 lenalidomide maintenance trial has not
conﬁrmed the prolongation of OS despite longer median fol-
lowup of 34 months. In this study, 614 patients who received
either VAD +/− DCEP (dexamethasone, cyclophosphamide,
etoposide, and cisplatin), or bortezomib and dexametha-
sone, as induction prior to ASCT were administered two
cycles of lenalidomide consolidation, at 25mg daily for three
of four weeks. Subsequently patients were randomized to
placebo or continuous lenalidomide 10–15mg daily until
relapse. The trial completed in mid-2010 with 34 months
of median followup after randomization. Although lenalido-
mide almost doubled PFS (42 versus 24 months, hazard ratio
HR 0.46, P<10
−8), deﬁnitive evidence for an OS beneﬁt
has not yet been reported. To our knowledge, at the time
of writing this paper, subgroup analyses (i.e., examination
of outcomes in patients with high-versus standard-risk MM)
are not yet available [34].
Further data will be forthcoming from ongoing trials,
such the Blood and Marrow Clinical Trials Network (CTN)
0702 protocol studying patients who have completed induc-
tion and who are then randomized to single ASCT, tandem
ASCT, or single ASCT followed by four cycles of RVD
consolidation. Additionally, a cooperative study between
the Dana-Farber Cancer Institute and IFM is investigating
shorter-course RVD pre- and post-ASCT versus longer RVD
induction without ASCT as part of the initial treatment6 Advances in Hematology
strategy. In all arms for both studies, patients will receive
lenalidomide maintenance. These trials and others will help
to clarify the role of lenalidomide for patients undergoing
ASCT.
2.4. Lenalidomide Maintenance and Secondary Malignancies.
Although maintenance lenalidomide is tolerable for patients,
generally causes few symptoms, and carries likely clinical
beneﬁts as pertains to long-term outcomes, it may come at
the price of secondary malignancies (SMs).
The above CALGB trial demonstrated more SMs in
patients on lenalidomide maintenance: 7.7% of 231 patients
on lenalidomide versus 1.7% of patients on placebo [33].
The IFM trial similarly showed SMs in 23 of 306 patients
(7.5%) on lenalidomide versus 6 of 302 patients (2%) on
placebo maintenance [34]. In both trials, SMs constituted a
diversecollectionofhematologicalandsolidtumors.Further
data from the IFM trial preliminarily hint at two key factors:
(1) the increased incidence of SMs emerged most promi-
nently 24 months after randomization; (2) in multivariate
analysis, predictors of SMs included not only lenalidomide
maintenance, but also advanced age, high ISS stage, male
gender, and DCEP induction therapy. Cytogenetics did not
predict SMs [34]. Current analyses are interrogating to
what extent the inclusion of the more leukemogenic DCEP
regimen on the IFM trial could explain at least part of these
diﬀerences, but the continued controversy on this subject
is highlighted by the fact that that placebo patients on
the CALGB trial were oﬀered cross-over into lenalidomide
maintenance, whereas the IFM has stopped lenalidomide in
that study, notably after patients had received 24 months of
lenalidomide maintenance already. Further clues regarding
the development of SMs may come from three other large
trials of prolonged lenalidomide in non-ASCT candidates
with MM, in which a very low incidence of SMs has been
observed [35, 36]. As an example, Palumbo et al. reported
their non-ASCT trial in which patients were randomized
to melphalan and prednisone (MP); melphalan, prednisone
and lenalidomide induction without maintenance (MPR);
or MPR induction followed by lenalidomide maintenance
(MPR-R). SMs occurred in 2 of 153, 6 of 152, and 4 of
150 patients on MP, MPR, and MPR-R, respectively. These
rates were statistically equivalent [36]. Given these data
showing virtually no increase in SMs in non-ASCT patients
on lenalidomide long term, it has been hypothesized that
the high-dose alkylator (i.e., melphalan) may play a key role
in the development of post-ASCT SMs when lenalidomide
maintenance is employed.
2.5. Lenalidomide Post-ASCT: Our Approach. Our group
favors maintenance therapy after ASCT. The doubling of
PFS in most trials with lenalidomide and the OS beneﬁt
in the CALGB trial weigh heavily in favor of that agent
despite the small but real risk of SMs after ASCT. It is
germane to the discussion of our practice to also mention
that bortezomib too has growing evidence favoring its
use in maintenance, especially in high-risk patients. When
given at some point during ASCT-based therapy (in some
trials only during induction, in others as maintenance),
bortezomib mitigates, but does not eliminate entirely, the
poor-prognosis implications of genetic markers such as the
t(4; 14) chromosomal translocation [37], and, more recently,
deletion of 17p in a trial by the HOVON cooperative
group [38]. As a result of these emerging data, our general
practice is to employ lenalidomide in the majority of MM
patients after ASCT who have standard-risk cytogenetics and
FISH, regardless of depth of response, and bortezomib in
patients with high-risk markers such as 17p deletion. We
do not prespecify a particular duration of maintenance with
either agent, although data from ongoing maintenance trials
may show in the future that limiting the time length of
maintenance therapy may be beneﬁcial.
3. Conclusions
This is an exciting time to care for MM patients. Novel
agents such as lenalidomide and bortezomib have markedly
lengthened survival for patients with MM and for the
ﬁrst time, we can begin to imagine turning MM into a
chronic disease-like hypertension, diabetes, or chronic myel-
ogenous leukemia. ASCT candidates especially enjoy a list of
treatment options that continues to expand. Lenalidomide
speciﬁcally is growing in importance in all stages of therapy
for the ASCT patient, and rightfully so, given its capacity
to induce deep remissions and extend both disease-free
and overall survival without excess toxicity in most cases.
How exactly to optimally incorporate lenalidomide into MM
therapy is becoming clearer with time, but existing data
can be diﬃcult to interpret given the panoply of single-arm
trialswithrelativelyshortfollowupandincompletereporting
of long-term, meaningful outcomes. Attention to long-term
followup from large, randomized trials currently in progress
will presumably enable us to employ this highly eﬀective
agent in a manner that achieves maximum beneﬁt.
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